We wrote this for you
Read our 2023 Year in Review to see our accomplishments over the past year as a global leader in diabetes research, patient care, and education.
Read our 2023 Year in Review to see our accomplishments over the past year as a global leader in diabetes research, patient care, and education.
UF Pediatric Endocrinology team ranked top 10 nationally Please join us in congratulating the UF Pediatric Endocrinology team for their recognition as the highest-ranked specialty at UF Health Shands Children’s Hospital and as a top 10 nationally ranked program by U.S. News & World Report! To read…
Welcome At the University of Florida Diabetes Institute, we are working together for a diabetes-free world.
Desmond Schatz, M.D. and Bimota Nambam, Ph.D. recently released new publications. Both investigators co-authored Immune Intervention in Type 1 Diabetes, which reviews recently published immune interventional and mechanistic studies in T1D subjects. The highlighted publications consist of primary (before the development of islet autoantibodies) and secondary prevention studies…
‘Photovoice’ (photos and captions) was used in this UF study to illustrate the differences in perspective between adolescents and parents regarding living with a child with T1D. The results showcase differences in opinion regarding food-mindfulness, freedom, and more.
UFDI Investigator Desmond Schatz, M.D. and collaborators found that the diagnosis of T1D in children and adolescents tends to be earlier if one parent a type 1 diabetic.
UFDI Investigator Desmond Schatz, M.D. and other researchers found that vitamin D insufficiency is present in a substantial proportion of youth with diabetes, particularly minorities, but the prevalence appears similar to that in youth without diabetes.
UFDI and nPOD investigators found that the presence of β-cells as well as insulitis several years after T1D diagnosis in children and young adults suggest that the chronicity of islet autoimmunity extends well into the post-diagnosis period.
UFDI investigators Desmond Schatz, M.D. and Anastasia Albanese-O’Neill, Ph.D. discuss patient participation in clinical trials in this diaTribe article.
UFDI investigators and collaborators found that granulocyte colony stimulating factor monotherapy did not affect C-peptide production, HbA1c, or insulin dose.This study supports the continued exploration of G-CSF and other mobilizing agents in subjects with T1D, but only when combined with immunodepleting agents where synergistic mechanisms of action have previously demonstrated…